Friday, 16 June 2017

Research Insights on Hepatocellular Carcinoma - Pipeline Review, H1 2017

Hepatocellular Carcinoma - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.
Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 78, 46, 3, 70, 14 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 10, 4, 1, 28 and 1 molecules, respectively.
Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AB Science SA AbbVie Inc Abivax SA Acceleron Pharma Inc Adaptimmune Therapeutics Plc Advenchen Laboratories LLC Alfact Innovation Amgen Inc AndroScience Corp ArQule Inc Array BioPharma Inc AstraZeneca Plc AVEO Pharmaceuticals Inc Bayer AG BeiGene Ltd Bio-Cancer Treatment International Ltd Biomics Biotechnologies Co Ltd Bioneer Corp Blueprint Medicines Corp Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Can-Fite BioPharma Ltd CASI Pharmaceuticals Inc CBT Pharmaceuticals Inc CCRP Therapeutics GmbH Celgene Corp Celldex Therapeutics Inc Celsion Corp China Medical System Holdings Ltd Chugai Pharmaceutical Co Ltd Conatus Pharmaceuticals Inc Delcath Systems Inc Dicerna Pharmaceuticals Inc Double Bond Pharmaceutical International AB eFFECTOR Therapeutics Inc Eiger BioPharmaceuticals Inc Eisai Co Ltd Eli Lilly and Company Endocyte Inc Epeius Biotechnologies Corp eTheRNA Immunotherapies NV Exelixis Inc F. Hoffmann-La Roche Ltd Faron Pharmaceuticals Oy Galaxy Biotech LLC Genelux Corp Genoscience Pharma Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc Golden Biotechnology Corp Green Cross Cell Corp Green Cross Corp H3 Biomedicine Inc HanAll Biopharma Co Ltd Horizon Pharma Plc Humorigin Biotechnology Corp Immatics Biotechnologies GmbH Immune Therapeutics Inc Immunicum AB Immunitor Inc Immunomedics Inc Immunovative Therapies Ltd In-Cell-Art SAS Incyte Corp Inovio Pharmaceuticals Inc Inspyr Therapeutics Inc InteRNA Technologies BV Jenrin Discovery Inc Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson KAHR medical Ltd Karcinolys SAS Kite Pharma Inc Komipharm International Co Ltd Kowa Company Ltd Les Laboratoires Servier SAS Ligand Pharmaceuticals Inc Lixte Biotechnology Holdings Inc MaxCyte Inc MedImmune LLC Medivir AB Merck & Co Inc Merck KGaA Merrimack Pharmaceuticals Inc Midatech Pharma Plc Millennium Pharmaceuticals Inc Mina Therapeutics Ltd MTG Biotherapeutics Inc MultiCell Technologies Inc NeuroVive Pharmaceutical AB NormOxys Inc Novartis AG NovaTarg Therapeutics Inc Nymox Pharmaceutical Corp Omeros Corp Oncolys BioPharma Inc OncoMed Pharmaceuticals Inc OncoTherapy Science Inc Oneness Biotech Co Ltd Ono Pharmaceutical Co Ltd Onxeo SA Otsuka Holdings Co Ltd Panacea Pharmaceuticals Inc PepVax Inc Peregrine Pharmaceuticals Inc Pfizer Inc Pharma Mar SA PharmAbcine Inc PharmaEssentia Corp Provecs Medical GmbH Provectus Biopharmaceuticals Inc Q BioMed Inc RedHill Biopharma Ltd Regulus Therapeutics Inc Saronic Biotechnology Inc Shenogen Pharma Group Ltd Sillajen Biotherapeutics Simcere Pharmaceutical Group Sun Pharma Advanced Research Company Ltd Taiwan Liposome Company Ltd Takeda Pharmaceutical Company Ltd TC BioPharm Ltd tella Inc Tessa Therapeutics Pte Ltd Therapure Biopharma Inc Theravectys SA Threshold Pharmaceuticals Inc Tiziana Life Sciences Plc TRACON Pharmaceuticals Inc Tumorend LLC UbiVac LLC VasGene Therapeutics Inc Vaxon Biotech Vect-Horus SAS Verlyx Pharma Inc VG Life Sciences Inc Vicus Therapeutics LLC Yooyoung Pharm Co Ltd
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home